Cargando…

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma

The recent advances in myeloma treatment result in significantly better outcomes, defined as increased progression free survival (PFS) and overall survival (OS). Since there is a proven correlation between the extend of response and prolonged survival, there is an urgent need for highly sensitive as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Agnieszka, Haussmann, Katy, Streitz, Mathias, Schlickeiser, Stephan, Tietze-Buerger, Carola, Blau, Igor Wolfgang, Uharek, Lutz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393516/ https://www.ncbi.nlm.nih.gov/pubmed/30814612 http://dx.doi.org/10.1038/s41598-019-39631-2

Ejemplares similares

Widely applicable, extended flow cytometric stem cell enumeration panel for quality control of advanced cellular products
por: Haussmann, Katy, et al.
Publicado: (2022)

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
por: Burmeister, Thomas, et al.
Publicado: (2012)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
por: Riebl, Veronika, et al.
Publicado: (2021)

Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma
por: Jiang, Duanfeng, et al.
Publicado: (2022)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
por: Wieczorek, Agnieszka, et al.
Publicado: (2016)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
por: Mendonça de Pontes, Robéria, et al.
Publicado: (2021)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
por: Krzywdzińska, Agnieszka, et al.
Publicado: (2021)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Safety of Therapeutic Apheresis in Children and Adolescents
por: Taylan, Christina, et al.
Publicado: (2022)

Batch Effects during Human Bone Marrow Stromal Cell Propagation Prevail Donor Variation and Culture Duration: Impact on Genotype, Phenotype and Function
por: Brachtl, Gabriele, et al.
Publicado: (2022)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates
por: Marini, Irene, et al.
Publicado: (2019)

Apheresis in Neurological Disorders
por: Dorst, Johannes
Publicado: (2020)

Apheresis and Covid-19
por: Griveas, Ioannis
Publicado: (2022)

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

Long-Term Signs of T Cell and Myeloid Cell Activation After Intestinal Transplantation With Cellular Rejections Contributing to Further Increase of CD16(+) Cell Subsets
por: Stobutzki, Nadja, et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

P828: EFFECT OF ANTI-CD38 MONOCLONAL ANTIBODIES ON THE INTERACTION OF MYELOMA CELLS WITH BONE MARROW STROMAL CELLS
por: Lienhart, Malgorzata, et al.
Publicado: (2023)

Therapeutic apheresis in autoimmune diseases
por: Bambauer, Rolf, et al.
Publicado: (2013)

Therapeutic Apheresis in Metabolic Syndrome
por: Voinov, V.A.
Publicado: (2018)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
por: Tapia-Alveal, Claudia, et al.
Publicado: (2020)

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
por: Anderson, Kenneth C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kvsuecd3l57uesccdnp3hj7or9